

11 June 2026

VITASORA RAISES \$4.0 MILLION IN PLACEMENT, CORNERSTONED BY A \$3.0 MILLION STRATEGIC INVESTMENT

Highlights

- Vitasora raises \$4.0 million via a strongly supported placement, approximately 2.7 times the Company's original \$1.5 million target, reflecting strong investor demand
- The Placement is cornerstoned by a \$3.0 million commitment from private investor Mr Bob Peters
- Directors intend to subscribe for upto a further \$250,000 of new shares on the same terms, subject to shareholder approval
- Monthly billings continue to accelerate: average daily billings have grown approximately 30% month on month and are up 70% since April 2026
- Funds will support the Company with commercialisation and scale-up of patient onboarding via Vitasora's vCare Electronic Medical Records (EMR) platform
- The Company expects monthly business-as-usual cashflow breakeven to occur during H2 of CY2026 and is now funded through to that milestone

Vitasora Health Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora" or "the Company"), a leader in AI-powered connected care and chronic disease management solutions, is pleased to announce that it has received firm commitments to raise approximately \$4.0 million (before expenses) via a placement to sophisticated, professional and institutional investors ("Placement"). The Placement was strongly supported, closing at approximately 2.7 times the Company's original \$1.5 million target.

The Placement will comprise the issue of 400 million fully paid ordinary shares ("Shares" or "New Shares") at an issue price of \$0.01 per Share to raise gross proceeds of approximately \$4.0 million (before costs). The issue price represents an 11% discount to the 15-day VWAP calculation. The New Shares will be issued within the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A, and accordingly no shareholder approval is required for their issue.

Cornerstone investment

The Placement is cornerstoned by a \$3.0 million commitment from private investor Mr Bob Peters (Peters Investments). Following allotment of the New Shares, Mr Peters is expected to become a substantial holder in the Company. The Board welcomes Mr Peters to the register and considers an investment of this scale by a single private investor to be a strong endorsement of the Company's strategy, its strong US-leadership team, vCare EMR platform and its pathway to cashflow breakeven.

Director participation


In addition to the Placement, the Directors of the Company intend to subscribe for upto \$250,000 of new shares on the same terms as the Placement, further aligning the Board with shareholders. Director participation is subject to shareholder approval under ASX Listing Rule 10.11, which will be sought at a general meeting of shareholders to be convened in due course. Further details will be set out in the Notice of Meeting.

The net proceeds of the Placement will be used to fund:

- Patient Management and Account Management
- Sales, business development, and marketing
- vCare Platform Enhancement & Roll-out
- Working capital and offer-related costs

Accelerating commercial momentum

The Placement follows a period of rapid and consistent growth in the Company's monthly billings. Average daily billings across the Company's Ceras and vCare programs (combined) have increased month on month throughout the current quarter, rising from US\$7,321 in April 2026 to US\$9,500 in May 2026 (up 30%) and US\$12,412 for June 2026 month-to-date (up a further 31%), an increase of 70% since April. Over the five most recent billing days, average daily billings were US\$13,262, approximately 81% above the April average.



*Average daily billings, (US\$). June 2026 reflects month-to-date actuals to 9 June 2026. Unaudited.

*# April/May metrics are based on billable care minutes delivered. Final Fee-For-Service (FFS) revenue is derived from reimbursable CPT codes generated from these activities, with validation currently underway following the vCare transition

Indicative Timetable

Trading halt lifted and shares recommence trading on the ASX	Thursday, 11 June 2026
Settlement of new Shares	Monday, 15 June 2026
Allotment and normal trading of New Shares	Wednesday, 17 June 2026
General meeting to approve Director participation	To be confirmed

The timetable is indicative only and remains subject to change at the Company's discretion, subject to compliance with applicable laws and the ASX Listing Rules.

Commenting on the outcome of the Placement, Marjan Mikel, CEO of Vitasora, said:

"This is a significant milestone for Vitasora. We sought \$1.5 million and closed \$4.0 million, anchored by Bob Peters' \$3.0 million investment. The raise validates our strategy, our platform and our execution. With billings accelerating, vCare scaling strongly, and a high-calibre U.S. team in place, we are funded through to monthly cashflow breakeven and focused on delivering growth.

"Nicholas Smedley, Non-Executive Chairman of Vitasora, added:

"Securing a \$3.0 million cornerstone commitment from a private investor of Bob Peters' calibre, alongside the Board's intention to invest on the same terms, is a powerful statement of confidence in Vitasora's strategy and execution. The Company asked the market for \$1.5 million and was met with demand of \$4.0 million. With the balance sheet now set, the Board's priority is disciplined delivery of the growth plan."

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley
Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.